Is Cytokinetics, Inc. overvalued or undervalued?

As of 2 August 2017, Cytokinetics, Inc. has moved from an expensive to a risky valuation grade. The company is currently considered overvalued, given its negative financial ratios, including a P/E ratio of NA due to losses, a Price to Book Value of -14.48, and an EV to Sales ratio of 187.15. These figures indicate significant challenges in profitability and valuation relative to its peers.
In comparison to its peers, Cytokinetics' EV to EBITDA stands at -6.47, while Bausch Health Cos., Inc. is rated as attractive with an EV to EBITDA of 9.0668, highlighting a stark contrast in valuation. Additionally, Cerevel Therapeutics Holdings, Inc. has a much lower EV to EBITDA of -15.8643, further emphasizing Cytokinetics' unfavorable position. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -30.61%, suggesting that investor sentiment aligns with the overvaluation assessment.